Bluejay Diagnostics, Inc. (NASDAQ:BJDX - Get Free Report) major shareholder Financial Lp Hrt sold 34,938 shares of Bluejay Diagnostics stock in a transaction on Friday, July 10th. The stock was sold at an average price of $1.40, for a total value of $48,913.20. Following the sale, the insider directly owned 92,055 shares of the company's stock, valued at $128,877. This represents a 27.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
Financial Lp Hrt also recently made the following trade(s):
- On Thursday, July 9th, Financial Lp Hrt bought 64,047 shares of Bluejay Diagnostics stock. The stock was acquired at an average cost of $1.51 per share, with a total value of $96,710.97.
Bluejay Diagnostics Stock Performance
BJDX stock opened at $1.22 on Tuesday. The company's 50-day simple moving average is $2.68 and its 200 day simple moving average is $2.48. Bluejay Diagnostics, Inc. has a 52 week low of $1.03 and a 52 week high of $16.68. The company has a market capitalization of $1.26 million, a PE ratio of -0.10 and a beta of 0.88.
Bluejay Diagnostics (NASDAQ:BJDX - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) EPS for the quarter.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Sell".
Read Our Latest Analysis on BJDX
Institutional Trading of Bluejay Diagnostics
A hedge fund recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 65,000 shares of the company's stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics at the end of the most recent reporting period. Hedge funds and other institutional investors own 18.47% of the company's stock.
About Bluejay Diagnostics
(
Get Free Report)
Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company's lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.
Leveraging a proprietary immunoassay platform, Bluejay's technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
